## **Supplementary Information File**

## Ferreira JN, et al. 2024

**Table S1.** List of primary and secondary antibodies and respective dilutions. AF - Alexa Fluor<sup>TM</sup>, HRP - horseradish peroxidase-conjugated

Antibody	Source	Catalog No.	Dilution
Rabbit monoclonal anti-AQP-5 IgG	Abcam	Ab92320	1:100
Rabbit polyclonal anti-KRT5 IgG	Abcam	Ab53121	1:100
Rabbit monoclonal anti-KRT14 IgG	Abcam	Ab181595	1:100
Mouse monoclonal anti-KRT19 lgG	Novus biologicals	NBP142238	1:100
Rabbit polyclonal anti-NKCC1 IgG	Abcam	Ab59791	1:100
Mouse monoclonal anti-GAPDH IgG	Santa Cruz	sc-365062	1:100
AF 594 goat anti-rabbit IgG	Abcam	Ab150080	1:200
AF 488 goat anti-rabbit IgG	Abcam	Ab150077	1:200
AF 488 goat anti-mouse IgG	Abcam	Ab150113	1:200
Goat anti-rabbit IgG, (H+L) HRP	Invitrogen	1TFS-AB-626120	1:3000
Goat anti-mouse IgG, (H+L) HRP	Invitrogen	1TFS-AB-626520	1:2000

**Table S2.** List of media, solutions and reagents used for LG primary cell isolation andorganoid culture. Please see reference 14 for more details.

Washing buffer	Final concentration	Volume (mL)
1XPBS	Not applicable	86.67
1XPBSPenicillin/Streptomycin (100%)	10%v/v	10
Bovine resum albumin (30%)	1%v/v	3.33
Total		100

Enzymatic dissociation buffer	Final concentration	Volume (mL)
1XPBS	Not applicable	1.763
1XPBSPenicillin/Streptomycin (100%)	1%v/v	0.020
Bovine resum albumin (30%)	1%v/v	0.067
Calcium chloride solution (50 mM)	1.25 mM	0.050
Collagenase II (40 mg/mL)	1 mg/mL	0.050
Hyaluronidase	1 mg/mL	0.050
Total		2

Basal media	Final concentration	Volume (mL)
DMEM/F12	Not applicable	98
L-Glutamine (100 mM)	1 mM	1
Penicillin/Streptomycin (100%)	1% v/v	1
Total		100

Expansion media (EM)	Final concentration	Volume (mL)
Basal media	Not applicable	94.85
Fetal bovine serum (100%)	5%v/v	5
EGF (20 µg/mL)	20 ng/mL	0.1
Total		100

Epithelial enrichment media (EEM)	Final concentration	Volume (mL)
Define Keratinocyte SFM	Not applicable	99.80
EGF (20 µg/mL)	20 ng/mL	0.1
FGF-10 (100 µg/mL)	50 ng/mL	0.05
FGF-7 (100 µg/mL)	50 ng/mL	0.05
Total		100

**Table S3.** Statistical analysis output from Z-score heatmap displayed in Fig. 2E comparing native LG tissue biopsies (NLG) with the LG organoid (LGO) experimental group (n=3/group). \* p-value < 0.05


Gene	Adjusted <i>p</i> -value	Gene	Adjusted <i>p</i> -value
BMP4	0.2381	NFYA*	0.0351
BMPR1A	0.1462	NLK	0.5193
BMPR2	0.8510	NRAS	0.6973
CD44	0.9681	PAFAH1B1	0.8893
CDH1	0.4199	PCGF6*	0.0209
CTBP1	0.8850	POU5F1	0.4099
CTNND1*	0.0097	PPARD	0.4860
DLX5*	0.0026	PPP2CA	0.1836
DVL3	0.8616	PPP2R1A	0.9474
EPAS1*	0.0008	PPP2R1B	0.3794
FGF2*	0.0009	PPP2R2A	0.1023
FOXD3	0.6509	PPP2R5B	0.9569
FZD1	0.2743	PPP2R5C	0.3583
FZD4	0.2950	PPP2R5E	0.2591
FZD7*	0.0125	PRKCH	0.0532
ID2*	0.0037	PRKCI	0.4339
ID4*	0.0059	RAF1	0.1154
IL6ST	0.1073	RHOA	0.5371
JARID2	0.0959	SMAD9	0.0780
KLF4	0.4105	SMARCAD1	0.8749
LEF1	0.5548	SOX2*	0.0331
LIF	0.5794	STAT3	0.2041
MAP2K4	0.1699	UTF1	0.1274
MAP3K7	0.9328	VIM	0.3848
MAPK11	0.7663	WNT10B	0.4816
MAPK14*	0.0499	WNT3*	0.0405
MEIS1	0.0537	WNT3A	0.3986
MYC*	0.0019	ZFHX3	0.1915

**Table S4.** Statistical analysis output from plotted Z-scores displayed in Fig. 3E comparing the LG organoid (LGO) with the senescence-induced LGO treated with etoposide (LGO+Eto) experimental groups (n=3/group). \*p-value < 0.05


Gene	Adjusted <i>p</i> -value
CASP3*	0.0276
CASP9	0.4140
SFN*	0.0004
TP53*	0.0071
CDC20*	0.0350
UBE2C*	0.0273
UBE2D1*	0.0003
CCNA2*	0.0006
CCNB1*	0.0085

**Table S5.** Statistical analysis output from plotted Z-scores displayed in Fig. 4G comparing the senescence-induced etoposide-treated LG organoid (LGO+Eto) with the etoposide-treated LG organoid transfected with Box A plasmid (LGO+Eto+BoxA) experimental groups (n=3/group). \**p*-value < 0.05


Gene	Adjusted <i>p</i> -value
HMGB1*	0.00130
CASP3*	0.04650
CASP9	0.96983
SFN*	0.00038
TP53*	0.01698
TUBA1C*	0.04881
VIM*	0.00171
CDC20*	0.01467
UBE2C*	0.01330
UBE2D1*	0.00693
CCNA2*	0.00005
CCNB1*	0.00156




**Figure S1.** Primary antibody validation and characterization for LG-like protein markers. SG – salivary gland. LG – lacrimal gland. Scale bar: 200  $\mu$ m.




**Figure S2.** Brightfield micrographs showing consistent biofabrication of LG spheroids by M3DB at 1 and 6 days of culture. Scale bar: 200 µm.




**Figure S3.** Plasmid transfection efficiency of Box A-GFP plasmid in differentiated LG cells. Epithelial enriched porcine LG cells cultured as a monolayer and were transfected with Box A plasmid at various of DNA content:Lipofectamine ratios. **A** The transfection efficiency was determined by observing GFP signal under a fluorescence microscope. **B** Transfected cells were quantified by automated cytometry using Countess 3 Automated Cell Counter and results were plotted as mean  $\pm$ S.D. \*\*\*\*p<0.0001 when compared with non-transfected cells or untreated control by a two-way ANOVA (n=3). LG cells treated with only Lipofectamine was recognized as a vehicle control. **C** Representative fluorescence micrograph displaying the Box A-GFP-expressed in epithelial-like LG cells. Scale bar: 100 µm.




**Figure S4.** Cell viability assessment by propidium iodide (PI) staining after LG cell transfection in monolayer cultures with Box A-GFP and Scramble-GFP plasmids. Scale bar: 200  $\mu$ m.



**Figure S5.** Brightfield micrographs showing the morphology of organoids assembled by magnetic bioprinting of primary LG cells up to 48h of culture after gene therapy (Box A HMGB1 or Scramble) and senescence induction by 10  $\mu$ M of etoposide. Scale bar: 200  $\mu$ m.



**Figure S6.** Brightfield micrographs after H&E staining for histological comparison and showing the morphology of the epithelial parenchyma with epithelial cells and matrix deposition in healthy LG organoids (LGO) and in LGO after aging induction without and with Box A gene therapy. The senescence-associated pathogenesis phenotype can be observed in the aging LGO without gene therapy. Scale bar: 50  $\mu$ m.



**Figure S7.** Full-length western blots used to produce Figure 5F. These images are the original and unprocessed versions. The top left blot for AQP5 and the lower one for GAPDH were cut prior to hybridization with antibodies, and a black dashed line was added to demarcate the membrane edges of the blots. Blot for NKCC1 has membrane edges visible. Predicted band sizes for: AQP5 – 28 kDa; NKCC1 – 130-180 kDa depending on glycosylation level; GAPDH - 37 kDa.